Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy.
Martínez
E
E
Infectious Diseases Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic Universitari, Barcelona, Spain.
García-Viejo
M A
MA
Marcos
M A
MA
Pérez-Cuevas
J B
JB
Blanco
J L
JL
Mallolas
J
J
Miró
J M
JM
Gatell
J M
JM
D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology / Q000517:prevention & control; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data*; D018791:CD4 Lymphocyte Count; D002555:Cerebrospinal Fluid / Q000382:microbiology; D018890:Chemoprevention; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D008297:Male; D016919:Meningitis, Cryptococcal / Q000382:microbiology / Q000517:prevention & control*; D008875:Middle Aged
D000935:Antifungal Agents; D015725:Fluconazole